Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab +/- Ipilimumab or Chemotherapy in Resectable NSCLC
NCT02259621Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2014
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of nivolumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Number of Participants With Grade 3 and 4 Lab Abnormalities, as Defined by CTCAE v4.03 at 8 weeks and Number of Grade 3 and 4 Adverse Events at 8 weeks. Started Sep 2014; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02259621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259621.